Publications: Meghan Ostertag

The International Monetary Fund found that the Chinese yuan is significantly undervalued, with Goldman Sachs estimating that the value of the currency is 25 percent below what is expected.

New research from the U.S. Census Bureau shows that venture capital investment and advanced technology adoption are closely linked to higher employment and productivity. VC-backed, technology-adopting firms account for a disproportionately large share of U.S. jobs, even as venture investment has declined since 2021.

AI isn’t destroying jobs; it’s creating them. At least in 2024, the surge in AI activity and data center construction generated more jobs than AI displaced.

The science community must move beyond the linear model of scientific research developed and encouraged by Vannevar Bush, and realign scientific exploration with national interests, especially in the face of the growing technological and economic threat posed by China.

China’s trade surplus has grown from $993 billion in 2024 to $1.08 trillion in the first 11 months of 2025, making it the first country in recorded history to reach the $1 trillion milestone.

From 1970 to the present, agricultural research conducted by a public research foundation in Brazil has increased Brazilian agricultural productivity by 110 percent.

Lowering tariffs with India would reinforce one of America’s most important emerging technology partnerships. Completing negotiations and sustaining investment would strengthen supply chains and enhance U.S. economic and strategic competitiveness.

Between 2015 and 2024, the cumulative VC investment gap came to $1.21 trillion.

In terms of purchasing power parity, U.S. per capita GDP has grown from 31 percent above the EU to 34 percent above it. About 72 percent of this gap can be attributed to differences in productivity, while just 28 percent is due to the difference in hours worked by Americans and Europeans.

Since the Inflation Reduction Act's passage, the number of industry-supported small-molecule cancer treatments entering post-approval trials in the United States has fallen by 45.3 percent.